Avenue Therapeutics Q1 EPS $(0.21) Up From $(0.62) YoY
Avenue Therapeutics Enters into Exclusive Worldwide License Agreement for ATX-04 for the Treatment of Pompe Disease
Avenue Therapeutics Q2 EPS $0.11 Up From $(6.43) YoY, Sales $1.404M
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Avenue Therapeutics shares are trading lower after the company reported worse-than-expected Q3 EPS results
Avenue Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
Avenue Therapeutics to Participate in Maxim Group’s 2024 Healthcare Virtual Summit
Allarity appoints Alex Epshinsky as CFO
Avenue Therapeutics to Participate in Upcoming Investor Conferences
Why MIRA Pharmaceuticals Shares Are Trading Higher By Around 45%; Here Are 20 Stocks Moving Premarket
Fortress Biotech Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights
Avenue Therapeutics: A Strong Buy on Promising AJ201 Developments and Strategic Initiatives
Avenue Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights
ATXI Stock Earnings: Avenue Therapeutics Misses EPS for Q2 2024
Avenue Therapeutics Stockholders Approve Key Proposals
Avenue Therapeutics to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
Avenue Therapeutics (ATXI) Gets a Buy from Maxim Group
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.